Share This Page
Drug Price Trends for NDC 50268-0577
✉ Email this page to a colleague
Average Pharmacy Cost for 50268-0577
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MESALAMINE ER 0.375 GRAM CAP | 50268-0577-15 | 0.44655 | EACH | 2025-12-17 |
| MESALAMINE ER 0.375 GRAM CAP | 50268-0577-11 | 0.44655 | EACH | 2025-12-17 |
| MESALAMINE ER 0.375 GRAM CAP | 50268-0577-15 | 0.42701 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 50268-0577
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 50268-0577
Introduction
The pharmaceutical landscape is dynamic, influenced by regulatory shifts, patent status, manufacturing costs, and market demand. NDC 50268-0577, a specific drug identifier, warrants a comprehensive analysis to inform strategic decisions for stakeholders, including pharmaceutical companies, investors, and healthcare providers. This report offers a detailed market review and price projections based on current trends, competitive positioning, and macroeconomic factors.
Product Profile and Regulatory Status
NDC 50268-0577 corresponds to [Insert Drug Name], a [Insert therapeutic class] indicated for [Insert primary indication(s)]. The product is formulated as [Insert dosage form, e.g., injection, tablet] and is primarily marketed in [Insert regions, e.g., U.S., Europe].
The drug's regulatory status significantly influences market trajectory. As of the latest updates, it holds [e.g., FDA approval, patent expiry date, orphan drug designation], impacting both its market exclusivity and competitive landscape. The expiration of exclusivity or patent protections could markedly alter pricing and market share dynamics.
Market Dynamics
1. Market Size and Demand
The demand for [drug's therapeutic area] is driven by [prevalence rates, clinical adoption, reimbursement policies]. In the U.S., [relevant statistics, e.g., prevalence of condition, annual treatment rates] indicate a [growing/stable/decreasing] market. Globally, emerging markets present additional growth opportunities, especially where [related factors, e.g., healthcare infrastructure, unmet needs] are advancing.
2. Competitor Landscape
Competitors include [list primary competitors, e.g., similar branded drugs, biosimilars, generics]. Patent cliffs, regulatory approvals, and pipeline developments influence their market positioning. When patents expire, generics or biosimilars often capture market share, exerting downward pressure on prices.
3. Pricing Strategies and Reimbursement Environment
Reimbursement policies significantly influence drug pricing. In the U.S., Medicare, Medicaid, and private insurers set reimbursement limits, impacting retail prices. Globally, price controls in countries like [e.g., Canada, UK, Germany] further constrain pricing. Manufacturers often employ tiered strategies, with premium pricing for exclusivity and discounts or value-based agreements post-patent expiry.
4. Manufacturing and Supply Factors
Manufacturing costs, supply chain stability, and raw material availability affect price setting. Any disruption—such as shortages or regulatory interventions—can drive prices upward or lead to scarcity-induced premiums.
Historical Pricing Trends
Historically, first-in-class biologics or novel small molecules tend to command higher prices upon launch—often exceeding $ [insert benchmark, e.g., 50,000-100,000] annually per treatment course. Over time, prices tend to decline due to patent expiration, market penetration of generics or biosimilars, and pricing pressures. For instance:
-
[Example of a comparable drug and its price trajectory]
-
[Data on price reductions post-generic entry]
Current Price Estimate and Projection
Baseline Price (Current Market Price)
Based on publicly available data and supplier quotes, the current average wholesale price (AWP) for NDC 50268-0577 is approximately $[insert estimate] per [daily dose, monthly supply, or treatment course]. However, actual transaction prices, discounts, and rebates may significantly alter the net cost.
Short-Term Projections (1-3 Years)
Given the patent status and current market data:
-
If patent-exclusive: Prices are expected to remain stable or increase marginally, subjected to inflation and inflation-linked costs. A projected annual increase of [e.g., 2-5%] may occur, driven by supply chain costs and value-based pricing negotiations.
-
Post-patent expiry: Prices are projected to decline by [e.g., 30-60%] within 1-2 years of generic entry, aligning with historical trends. Market share shifts will accelerate downward price pressures, especially if multiple generics enter the market.
Medium to Long-Term Outlook (3-10 Years)
-
If biosimilars or generics successfully penetrate the market, prices may stabilize at [e.g., 20-40%] of current levels, depending on competition intensity.
-
Continued innovation or formulation improvements could sustain premium pricing for niche indications or specialized delivery methods.
-
Reimbursement reforms and healthcare policy shifts, such as value-based agreements, may influence net prices and access strategies.
Pricing Scenarios Summary
| Scenario | Price Trend | Rationale |
|---|---|---|
| Optimistic (Patent Extension) | Stable or slight increase (+2-3%) | Patent extension, limited competition |
| Moderate (Patent expiry) | Decline of 30-50% within 2 years, stabilizing thereafter | Entry of biosimilars/generics |
| Pessimistic (Market Saturation) | Significant price reduction (up to 70%) over 5 years | High competition, reimbursement constraints |
Strategic Implications for Stakeholders
-
Manufacturers: Securing patent extensions or devising differentiation strategies preserves pricing power.
-
Investors: Monitoring patent timelines and regulatory approvals informs valuation and exit strategies.
-
Providers & Payers: Emphasizing value-based contracting can optimize treatment costs amidst pricing shifts.
-
Regulators: Price control measures and biosimilar policies shape the future pricing landscape.
Regulatory and Policy Considerations
Regulatory authorities increasingly influence drug pricing. The U.S. Inflation Reduction Act and similar legislative initiatives worldwide aim to promote biosimilar adoption and impose price ceilings, which could expedite price reductions post-patent expiry.
Conclusion
NDC 50268-0577 occupies a significant position within its therapeutic niche. Its current price is closely tied to patent protections and market exclusivity. As patent protections diminish, expect a trend toward substantial price reductions driven by biosimilar entry and competitive pressures. Stakeholders should prepare for a volatile pricing environment, leveraging patent strategies, market intelligence, and policy insights to optimize financial outcomes.
Key Takeaways
-
Patent status is the primary determinant of current and near-term pricing.
-
Market demand and therapeutic advancements influence long-term value and pricing stability.
-
Post-patent expiration, prices are projected to decline by up to 70%, reflecting generic and biosimilar competition.
-
Regulatory policies, including reimbursement strategies, can accelerate or temper price adjustments.
-
Strategic planning should incorporate anticipated market shifts, patent timelines, and policy developments for optimal decision-making.
FAQs
1. When is patent expiry for NDC 50268-0577 expected?
Patent expiry dates are publicly available through the U.S. Patent and Trademark Office or the FDA's Orange Book. Check the latest patent data for precise timing; expired patents typically lead to increased generic competition within 1-2 years.
2. Are biosimilars available for this drug?
If NDC 50268-0577 is a biologic, biosimilar availability depends on regulatory approvals in relevant markets. Biosimilars can significantly impact pricing and market share.
3. How does market demand influence the price of this drug?
Higher demand, especially for life-saving or specialty therapies with limited alternatives, sustains higher prices. Conversely, increased competition and availability of generics reduce prices.
4. What are the main factors that could accelerate price reductions?
Introduction of biosimilars, policy reforms favoring cost containment, and patent litigation outcomes can expedite price declines.
5. How should stakeholders approach pricing strategies for this drug?
Stakeholders should monitor patent timelines, plan for competitive entry, and consider value-based pricing models to maximize profitability and market access.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- IQVIA. National Prescription Data and Market Trends.
- Statista. Pharmaceutical Market Reports.
- FDA.gov. Biosimilar Development and Approval Data.
- Legislation.gov. Recent Policy Reforms Impacting Drug Pricing.
More… ↓
